<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04411706</url>
  </required_header>
  <id_info>
    <org_study_id>CTGU005</org_study_id>
    <nct_id>NCT04411706</nct_id>
  </id_info>
  <brief_title>A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>a Phase II, Open-label, Single Arm Study of Sintilimab (an Anti-PD-1 Inhibitor) Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xin-Hua Xu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Three Gorges University, Yichang, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy and safety of Sintilimab (an Anti-PD-1 Inhibitor)
      combined with apatinib and capecitabine as first-line therapy in patients with advanced
      hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>1 year after the last patient's enrollment</time_frame>
    <description>Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>1 year after the last patient's enrollment</time_frame>
    <description>Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>1 year after the last patient's enrollment</time_frame>
    <description>Duration of Response (DoR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>1 year after the last patient's enrollment</time_frame>
    <description>the date of Death of any causes since the date of enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>1 year after the last patient's enrollment</time_frame>
    <description>Progression-free survival(PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by the rate of AEs</measure>
    <time_frame>1 year after the last patient's enrollment</time_frame>
    <description>The incidence and severity of adverse events (AEs) and serious adverse events (SAEs)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sintilimab+Apatinib+Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>=Drug: Sintilimab（i.v）+apatinib（p.o）+capecitabine（p.o）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab Combined With Apatinib and Capecitabine</intervention_name>
    <description>Drug: Sintilimab 200mg (3mg/kg for underweight patients) intravenously, every 21 days for a cycle;
Drug: Apatinib,250mg po qd, for continuous medication;
Drug: Capecitabine,1000mg/m2 po bid, d1-d14, every 21 days for a cycle;</description>
    <arm_group_label>Sintilimab+Apatinib+Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has given written informed consent.

          2. Age between 18-75 years old.male or female.

          3. Conform to the clinical diagnosis standard strictly or histological or cytological
             confirmation of HCC(hepatocellular carcinoma) and with at least one measurable lesion
             by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to
             RECIST 1.1 standard.

          4. Subjects haven't received any systemic treatment that includes target-therapy,
             immunotherapy or chemotherapy for HCC before admission.

          5. liver function status Child-Pugh Class A; Barcelona Clinic Liver Cancer(BCLC) staging
             is stage B or C；

          6. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1；

          7. Expected survival ≥12 weeks

          8. The main organ's function is normal and it should meet the following criteria(Excludes
             use of any blood components and cell growth factors during the screening period):

               1. Absolute neutrophil count≥1.5×109 /L

               2. Platelets≥80×109/L ;Hemoglobin≥9.0 g/dL; Serum albumin≥3g/dL

               3. Total bilirubin (TBIL)≤1.5×upper limit of normal (ULN); ALT and AST≤1.5×upper
                  limit of normal(ULN); AKP≤ 2.5×upper limit of normal(ULN)

               4. Thyroid stimulating hormone (TSH)≤1.0×upper limit of normal(ULN)（If abnormal, T3
                  and T4 levels should be examined at the same time）

               5. Serum creatinine ≤1.5×ULN or creatinine clearance &gt; 50 mL/minute (using
                  Cockcroft-Gault formula)

        Exclusion Criteria:

          1. Patients must not have had prior treatment with Sintilimab or any other PD-L1 or PD-1
             antagonists.

          2. Patients with any active autoimmune disease or history of autoimmune disease,
             including but not limited to the following: hepatitis, pneumonitis, uveitis, colitis
             (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism,
             and hypothyroidism, except for subjects with vitiligo or resolved childhood
             asthma/atopy. Asthma that requires intermittent use of bronchodilators or other
             medical intervention should also be excluded.

          3. Concurrent medical condition requiring the use of immunosuppressive medications, or
             immunosuppressive doses of systemic or absorbable topical corticosteroids. Doses &gt; 10
             mg/day prednisone or equivalent are prohibited within 2 weeks before study drug
             administration. Note: corticosteroids used for the purpose of IV contrast allergy
             prophylaxis are allowed.

          4. Known history of hypersensitivity to any components of the Sintilimab formulation, or
             other antibody formulation.

          5. Active central nervous system (CNS) metastases with clinical symptoms (including
             cerebral edema, steroid requirement, or progressive disease).

          6. Patients with other malignant tumor (except cured skin basal cell carcinoma and
             cervical carcinoma).

          7. Clinically significant cardiovascular and cerebrovascular diseases, including but not
             limited to severe acute myocardial infarction within 6 months before enrollment,
             unstable or severe angina, or coronary artery bypass surgery, Congestive heart failure
             (New York heart association (NYHA) class &gt; 2), ventricular arrhythmia which need
             medical intervention, left ventricular ejection fraction(LVEF) &lt; 50%.

          8. Hypertension and unable to be controlled within normal level following treatment of
             anti-hypertension agents(within 3 months): systolic blood pressure &gt; 140 mmHg,
             diastolic blood pressure &gt; 90 mmHg.

          9. Coagulation abnormalities (PT&gt;16s、APTT&gt;43s、TT&gt;21s、Fbg&lt;2g/L), with bleeding tendency or
             are receiving thrombolytic or anticoagulant therapy. Patients with or previous with
             serious hemorrhage (bleeding &gt; 30 ml within 3 months), haemoptysis (&gt; 5 ml within 4
             weeks) of thromboembolic events within 12 months (including stroke events and/or
             transient ischemic attack).

         10. Previous digestive tract bleeding history within 3 months or evident gastrointestinal
             bleeding tendency, such as: esophageal varices, local active ulcerative lesions,
             gastric ulcer and duodenal ulcer, the ulcerous colitis, gastrointestinal diseases such
             as portal hypertension or resection of tumor with bleeding risk, etc.

         11. Objective evidence of previous or current pulmonary fibrosis history, interstitial
             pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, pulmonary
             function damaged seriously etc.

         12. History of immunodeficiency including seropositivity for human immunodeficiency virus
             (HIV), or other acquired or congenital immune-deficient disease, or active hepatitis
             (transaminase does not meet the inclusion, hepatitis B virus (HBV) DNA ≥10⁴ /ml or
             hepatitis C virus (HCV) RNA≥103 /ml or higher)

         13. Participated in other clinical trials, or finish other clinical trials within 4 weeks.
             Patients who may receive other anti-tumor systemic chemotherapy during the study.

         14. Patients who may receive vaccination during the study, or previous had vaccination
             within 4 weeks.

         15. Any other medical, psychiatric, or social condition deemed by the investigator to be
             likely to interfere with a subject's rights, safety, welfare, or ability to sign
             informed consent, cooperate, and participate in the study or would interfere with the
             interpretation of the results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xinhua Xu, Master</last_name>
    <phone>+8613986747496</phone>
    <phone_ext>+8613986747496</phone_ext>
    <email>2732774352@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lu Xu, Phd</last_name>
    <phone>+8613972032135</phone>
    <email>xlnick@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University</name>
      <address>
        <city>Yichang</city>
        <state>Hubei</state>
        <zip>443003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinhua Xu</last_name>
      <phone>+8613986747496</phone>
      <phone_ext>+8613986747496</phone_ext>
      <email>2732774352@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>China Three Gorges University, Yichang, China</investigator_affiliation>
    <investigator_full_name>Xin-Hua Xu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

